@article{88b065fecae84aa18d15ba45ddd36382,
title = "Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.",
author = "Sharman, \{Jeff Porter\} and Coutre, \{Steven E.\} and Furman, \{Richard R.\} and Cheson, \{Bruce D.\} and Pagel, \{John M.\} and Peter Hillmen and Barrientos, \{Jacqueline Claudia\} and Zelenetz, \{Andrew David\} and Kipps, \{Thomas J.\} and Ian Flinn and Paolo Ghia and Hallek, \{Michael J.\} and Bertrand Coiffier and OBrien, \{Susan Mary\} and Eugen Tausch and Kreuzer, \{Karl A\} and Wendy Jiang and Jahn, \{Thomas Michael\} and Mirella Lazarov and Stephan Stilgenbauer",
note = "Background: Idelalisib (IDELA) is a potent and selective inhibitor of PI3Kδ, which is critical for activation, proliferation and survival of B cells and their homing and retention in lymphoid tissues. An unmet need exists for effective therapies in patients with CLL positive for del(17p) and other adverse prognostic factors.",
year = "2014",
month = may,
day = "20",
language = "American English",
volume = "32",
journal = "Journal of Clinical Oncology",
}